About Alterity Therapeutics Limited
https://alteritytherapeutics.comAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.
CEO
David A. Stamler
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-09 | Reverse | 1:10 |
| 2016-03-24 | Reverse | 1:6 |
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
TWIN LAKES CAPITAL MANAGEMENT, LLC
Shares:139.26K
Value:$462.64K
MORGAN STANLEY
Shares:68.68K
Value:$228.18K
HB WEALTH MANAGEMENT, LLC
Shares:58.46K
Value:$194.22K
Summary
Showing Top 3 of 20
About Alterity Therapeutics Limited
https://alteritytherapeutics.comAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $3.83M ▲ | $10.86M ▲ | $-4.97M ▲ | -129.78% ▲ | $-0.42 ▲ | $-7.11M ▲ |
| Q2-2025 | $1.61M ▼ | $9.03M ▼ | $-7.17M ▲ | -446.68% ▲ | $-0.84 ▲ | $-7.53M ▲ |
| Q4-2024 | $2.12M ▲ | $14.98M ▲ | $-12.62M ▼ | -595.51% ▼ | $-1.2 ▲ | $-14.62M ▼ |
| Q2-2024 | $1.9M ▲ | $8.45M ▲ | $-6.51M ▼ | -342.35% ▲ | $-1.56 ▼ | $-8.33M ▼ |
| Q4-2023 | $1.53M | $7.72M | $-5.77M | -377.3% | $-1.44 | $-7.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $40.66M ▲ | $46.03M ▲ | $3.62M ▲ | $42.4M ▲ |
| Q2-2025 | $4.54M ▼ | $10.55M ▼ | $2.76M ▼ | $7.79M ▼ |
| Q4-2024 | $12.64M ▲ | $19.22M ▼ | $5.43M ▲ | $13.8M ▼ |
| Q2-2024 | $12.32M ▼ | $22.19M ▼ | $4.57M ▲ | $17.62M ▼ |
| Q4-2023 | $15.77M | $27.32M | $4.5M | $22.81M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $0 ▲ | $-2.36M ▲ | $-7.5M ▼ | $25.24M ▲ | $15.2M ▲ | $-2.36M ▲ |
| Q2-2025 | $-7.17M ▲ | $-8.36M ▼ | $0 ▲ | $369.32K ▼ | $-4.75M ▼ | $-8.36M ▼ |
| Q4-2024 | $-12.62M ▼ | $-8.11M ▼ | $-722 ▲ | $8.17M ▲ | $318.46K ▲ | $-8.11M ▼ |
| Q2-2024 | $0 | $-4.49M ▲ | $-1K ▲ | $970K ▲ | $-4.39M ▲ | $-4.86M ▲ |
| Q4-2023 | $0 | $-10.11M | $-26.58K | $-12.76K | $-25.34M | $-6.2M |
CEO
David A. Stamler
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-09 | Reverse | 1:10 |
| 2016-03-24 | Reverse | 1:6 |
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
TWIN LAKES CAPITAL MANAGEMENT, LLC
Shares:139.26K
Value:$462.64K
MORGAN STANLEY
Shares:68.68K
Value:$228.18K
HB WEALTH MANAGEMENT, LLC
Shares:58.46K
Value:$194.22K
Summary
Showing Top 3 of 20